You have 9 free searches left this month | for more free features.

ipatasertib

Showing 1 - 25 of 40

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Solid Tumors Trial in Shanghai City (Ipatasertib)

Active, not recruiting
  • Solid Tumors
  • Ipatasertib
  • Shanghai City, China
    Fudan University Shanghai Cancer Center
Jan 8, 2023

Triple Negative Breast Cancer Trial in London (Atezolizumab, Ipatasertib, Paclitaxel)

Active, not recruiting
  • Triple Negative Breast Cancer
  • London, United Kingdom
    Barts Health NHS Trust
Aug 10, 2022

Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial (Biopsy,

Not yet recruiting
  • Locally Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Nov 8, 2022

Castrate Resistant Prostate Cancer Trial in Chicago, Indianapolis, Hershey (Ipatasertib, Darolutamide, Androgen Deprivation

Recruiting
  • Castrate Resistant Prostate Cancer
  • Ipatasertib
  • +2 more
  • Chicago, Illinois
  • +2 more
Jul 19, 2022

Metastatic Breast Cancer Trial in Spain (Ipatasertib, Trastuzumab, Pertuzumab)

Recruiting
  • Metastatic Breast Cancer
  • Ipatasertib
  • +2 more
  • Badalona, Barcelona, Spain
  • +9 more
Oct 24, 2022

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic

Not yet recruiting
  • FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
  • +4 more
  • Computed Tomography
  • +3 more
  • (no location specified)
Sep 13, 2022

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma

Recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +17 more
  • Biopsy
  • +3 more
  • Augusta, Georgia
  • +4 more
Jan 25, 2023

Cancer Trial (Ipatasertib)

Not yet recruiting
  • Cancer
  • Ipatasertib
  • (no location specified)
May 16, 2023

Breast Cancer Trial in Boston (Ipatasertib, Fulvestrant, Aromatase Inhibitor)

Recruiting
  • Breast Cancer
  • Ipatasertib
  • +3 more
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
Oct 25, 2021

Breast Cancer Trial in Worldwide (Ipatasertib, Placebo, Palbociclib)

Active, not recruiting
  • Breast Cancer
  • Ipatasertib
  • +3 more
  • Atlanta, Georgia
  • +19 more
Dec 5, 2022

Triple Negative Breast Cancer Trial in Portugal, Spain (Ipatasertib, Capecitabine, Eribulin)

Recruiting
  • Triple Negative Breast Cancer
  • Ipatasertib
  • +4 more
  • Amadora, Lisboa, Portugal
  • +16 more
Jun 10, 2022

NSCLC Stage IV, NSCLC Stage IIIB Trial in United States (Ipatasertib)

Recruiting
  • NSCLC Stage IV
  • NSCLC Stage IIIB
  • Ipatasertib
  • Fairway, Kansas
  • +4 more
Nov 29, 2021

Breast Cancer Trial in Worldwide (Ipatasertib, Paclitaxel, Atezolizumab)

Completed
  • Breast Cancer
  • Ipatasertib
  • +4 more
  • Long Beach, California
  • +17 more
Apr 22, 2022

Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +23 more
  • Biospecimen Collection
  • +2 more
  • Los Angeles, California
  • +1 more
Jul 7, 2022

Breast Cancer Trial in Villejuif (Atezolizumab Injection, Ipatasertib, Bevacizumab)

Recruiting
  • Breast Cancer
  • Atezolizumab Injection
  • +4 more
  • Villejuif, France
    Gustave Roussy
Mar 9, 2022

Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced

Recruiting
  • Head and Neck Carcinoma of Unknown Primary
  • +24 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Aug 6, 2022

Early-stage Breast Cancer Trial in Heidelberg (Atezolizumab 1200 mg in 20 ML Injection, Inavolisib, Ipatasertib)

Not yet recruiting
  • Early-stage Breast Cancer
  • Atezolizumab 1200 mg in 20 ML Injection
  • +5 more
  • Heidelberg, Baden-Wuerttemberg, Germany
    National Center for Tumor Diseases
Sep 13, 2022

Tumors Trial in Worldwide (5-FU, Docetaxel, Enzalutamide)

Completed
  • Neoplasms
  • San Francisco, California
  • +10 more
Jan 6, 2022

Metastatic or Locally Advanced Malignancies Trial in Germany (Vemurafenib, Cobimetinib, Atezolizumab)

Recruiting
  • Metastatic or Locally Advanced Malignancies
  • Berlin, Germany
  • +5 more
Jan 2, 2023

Breast Cancer Trial in Australia, Canada, New Zealand (Ipatasertib, Fulvestrant, Placebo)

Recruiting
  • Breast Cancer
  • Ipatasertib
  • +2 more
  • Bowral, New South Wales, Australia
  • +37 more
Aug 8, 2022

Gastric Cancer Trial in Worldwide (5-Fluorouracil, Ipatasertib, Leucovorin)

Completed
  • Gastric Cancer
  • Los Angeles, California
  • +33 more
Feb 18, 2022

Prostate Cancer Trial in Worldwide (Abiraterone, Apitolisib, Ipatasertib)

Completed
  • Prostate Cancer
  • Scottsdale, Arizona
  • +58 more
Sep 7, 2022

Ovarian Tumors Trial in New York (Ipatasertib, Paclitaxel)

Withdrawn
  • Ovarian Neoplasms
  • New York, New York
    Dubin Breast Center
Oct 2, 2020

Prostate Cancer Trial in Canada (Adavosertib, Savolitinib, Darolutamide)

Recruiting
  • Prostate Cancer
  • Edmonton, Alberta, Canada
  • +10 more
May 9, 2022

Endometrial Cancer Trial in United States (Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib)

Recruiting
  • Endometrial Cancer
  • Atezolizumab - 28 Day Cycle
  • +6 more
  • Duarte, California
  • +13 more
Jun 8, 2022